Business Context and Reporting Period
Company: Boston Scientific Corporation (BSX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 18, 2026
Event: Announcement of an Investment Agreement with MiRus LLC, a developer of proprietary biomaterials and procedural solutions for cardiovascular and orthopedic diseases.
Key Financial Metrics and Transaction Details
This filing details a strategic investment rather than standard periodic financial results. Key financial terms include:
- Initial Cash Payment: $1.5 billion paid on May 15, 2026 (exclusive of a prior $100 million payment).
- Equity Stake Acquired: 33.75% of MiRus's fully diluted non-voting common equity interests.
- Call Option Value: An exclusive option to acquire 100% of a new subsidiary ("TAVR-Structural Heart NewCo") holding the Siegel transcatheter aortic valve replacement (TAVR) System assets for an additional $3.0 billion in aggregate cash payments.
- Contingent Payments: Potential additional payments to MiRus based on net sales of the TAVR System if the Call Option is exercised.
- Additional Option: Exclusive option to acquire mitral and tricuspid replacement valve assets from MiRus for an additional payment (amount not specified).
Note: The filing does not provide standard revenue, profit, cash flow, margin, or debt metrics for the reporting period.
Material Changes and Transaction Structure
The primary material change is the entry into the Investment Agreement with MiRus LLC. The transaction structure includes:
- Target Asset: The Siegel TAVR System, which has received FDA investigation device exemption approval to conduct the STAR randomized control clinical trial in the U.S.
- Conditions for Call Option: The $3.0 billion acquisition of the TAVR-Structural Heart NewCo is subject to MiRus achieving certain clinical and regulatory milestones.
- Forfeiture Clause: If Boston Scientific does not exercise the Call Option or make additional payments within the applicable period, its 33.75% equity interest in MiRus will be forfeited or reduced by approximately 75%, or exchanged for an interest in the NewCo.
Outlook, Risks, and Management Commentary
Management Outlook: The investment is intended to secure access to novel biomaterials and the Siegel TAVR System, pending successful clinical trials and regulatory approvals.
Risks and Contingencies: The filing includes extensive forward-looking statements and risk factors, including:
- Regulatory Risk: Failure to obtain Premarket Approval (PMA) for the TAVR System or delays in regulatory clearances.
- Clinical Risk: Variations in outcomes of the STAR clinical trial or future market studies.
- Execution Risk: Uncertainty regarding the closing of the Call Option, integration of acquisitions, and achievement of anticipated benefits.
- Market and Operational Risks: Economic conditions, reimbursement changes, supply chain disruptions, and competitive pressures.
Key Facts for Investor Verification
- Verify the specific clinical and regulatory milestones required to trigger the $3.0 billion Call Option exercise.
- Confirm the status and timeline of the STAR randomized control clinical trial for the Siegel TAVR System.
- Assess the total potential capital outlay, including the initial $1.6 billion ($1.5B + $0.1B), the potential $3.0 billion option, and unspecified payments for mitral/tricuspid assets.
- Review the terms regarding the forfeiture or reduction of the initial 33.75% equity stake if the Call Option is not exercised.
- Monitor future filings for updates on the integration of MiRus assets and any changes to the investment structure.